Ocular Therapeutix has announced that they will attend and present at the Angiogenesis, Exudations, and Degeneration 2021 Meeting, which is being held virtually due to the pandemic. They intend to explain data from the Phase 1 trial of OTX-TKI, a treatment for wet age-related macular degeneration (wAMD) and a number of other conditions that impact the retina.

About Wet Macular Degeneration

According to the Mayo Clinic, wet macular degeneration is one of two forms of macular degeneration. The other form, which is the dry type, is much more common. This chronic eye disorder leads to blurred vision or a blind spot in one’s visual field. In most cases, abnormal blood vessels grow into the macula before releasing blood or other fluids. These fluids then impact retinal function. Fluid can also leak from the choroid, which would cause a bump to form in the macula. Medical professionals aren’t quite sure why this happens, but they do know that it leads to symptoms like visual distortions, blurry spots in the field of vision, reduced central vision, trouble recognizing faces, issues with adapting to changes in light, lower brightness and intensity of colors, and problems reading due to the blurriness of print. There are treatments available; doctors may prescribe Eylea, Lucentis, Beovu, or Avastin. They may also utilize photodynamic therapy, low vision rehabilitation, and photocoagulation. All of these options can work together to slow disease progression, stop further vision loss, and possibly even recover some of the lost vision.

About the Presentation

Ocular Therapeutix will give their presentation, which is titled Intravitreal Hydrogel-Based Axitinib Implant (OTX-TKI) for the Treatment of Neovascular AMD: Phase 1 Trial Update, at the Angiogenesis, Exudations, and Degeneration 2021 Meeting. They will give updates on the Phase 1 trial of OTX-TKI, an injected version of axitinib delivered via intravitral implant. You can find out more about the presentation on Ocular’s website.

Find the source article here.